When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SNGX - Soligenix to boost enrolment in late-stage study of SGX942 in oral mucositis
Soligenix Inc.
Based on a preplanned interim analysis, the independent Data Monitoring Committee (DMC) has recommended that the Phase 3 DOM-INNATE study evaluating Soligenix's (NASDAQ:SNGX) SGX942 (dusquetide) for the treatment of oral mucositis in head and neck cancer patients receiving chemoradiation therapy increase enrollment by ~70 subjects (from 190 to 260) in order to maintain the 90% statistical power for the primary endpoint. The higher number of participants should enable the study to account for potential variability and/or distribution changes in the patient population versus the initial protocol design assumptions. No safety issues were reported.
More news on: Soligenix, Inc., Healthcare stocks news,